60 Degrees Pharmaceuticals shares are trading higher after the company announced FDA orphan drug designation for tafenoquine to treat acute babesiosis.
Portfolio Pulse from Benzinga Newsdesk
60 Degrees Pharmaceuticals shares are trading higher after the company announced FDA orphan drug designation for tafenoquine to treat acute babesiosis.
June 11, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
60 Degrees Pharmaceuticals (SXTP) shares are trading higher following the FDA's orphan drug designation for tafenoquine to treat acute babesiosis.
The FDA's orphan drug designation is a significant regulatory milestone that can lead to market exclusivity and potential financial incentives, driving investor optimism and a positive short-term impact on SXTP's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100